Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 4Phase 1 4Phase 3 2Phase NA 1Phase EARLY_PHASE1 1Phase 4 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Giant Cell Tumor of Tendon Sheath 1

Interventions

fludarabine 9Cyclophosphamide 9pembrolizumab 5Oncolytic Virotherapy 4Nivolumab 4Cholestanetriol 26-Monooxygenase 3atezolizumab 2alpha-Synuclein 2Trastuzumab 2Influenza Vaccines 2Blood Specimen Collection 2Ascorbic Acid 2tinostamustine 1sugemalimab 1spartalizumab 1ruxolitinib 1reolysin 1pexidartinib 1methyl prednisolonate 1irinotecan sucrosofate 1fiu protein, E coli 1camrelizumab 1avelumab 1apatinib 1VTX-2337 1Temozolomide 1TAK-981 1Sorafenib 1Radiation 1RXDX-106 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × INDUSTRY × pexidartinib × Clear all
NCT04223635 2021-06-22

Study of Pexidartinib in Participants With Moderate Hepatic Impairment Compared With Healthy Participants

Daiichi Sankyo

Phase EARLY_PHASE1 Completed
16 enrolled 22 charts

Giant Cell Tumor of Tendon Sheath

Data powered by HemOnc (CC BY 4.0) Colophon âš¡